Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

Biology of Incretins: GLP-1 and GIP

Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works

Insulin resistance and cardiovascular disease

Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358 · see citing works

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works

Incretin-based therapies for type 2 diabetes mellitus

Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645 · see citing works

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor

Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 618 · see citing works

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 582 · see citing works

Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.

Lewis, G., Uffelman, K., Szeto, L., Weller, B., & Steiner, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117633 · Cited by 533 · see citing works

Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway

Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · see citing works

GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting

Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · see citing works

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336 · see citing works

Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals

Lewis, G. F., Uffelman, K. D., Szeto, L., & Steiner, G. A. (1993) · Diabetes · doi:10.2337/diab.42.6.833 · Cited by 323 · see citing works

Fatty acid regulation of very low density lipoprotein production

Lewis, G. F. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00004 · Cited by 296 · see citing works

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · see citing works

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2009) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 276 · see citing works

Fasting and Postprandial Overproduction of Intestinally Derived Lipoproteins in an Animal Model of Insulin Resistance

Haidari, M., Leung, N. M., Mahbub, F., Uffelman, K. D., Avramoglu, R. K., Lewis, G. F., & Adeli, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200544200 · Cited by 269 · see citing works

Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect

Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199 · see citing works

Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance

Adiels, M., Westerbacka, J., Soro‐Paavonen, A., Häkkinen, A. ‐., Vehkavaara, S., CASLAKE, M. J., Packard, C. J., Olofsson, S.-O., Yki‐Järvinen, H., Taskinen, M., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0790-1 · Cited by 197 · see citing works

Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.

Malmström, R., Packard, C. J., CASLAKE, M. J., Bedford, D. K., Stewart, P., Yki‐Järvinen, H., Shepherd, J., & Taskinen, M. (1998) · Diabetes · doi:10.2337/diabetes.47.5.779 · Cited by 197 · see citing works

Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding.

Cohn, J. S., Wagner, D. A., Cohn, S. D., Millar, J. S., & Schaefer, E. J. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114507 · Cited by 193 · see citing works

Hyperinsulinemia Is Associated With Increased Production Rate of Intestinal Apolipoprotein B-48–Containing Lipoproteins in Humans

Duez, H., Lamarche, B., Uffelman, K. D., Valéro, R., Cohn, J. S., & Lewis, G. F. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000222015.76038.14 · Cited by 188 · see citing works

Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men

Malmström, R., Packard, C. J., Watson, T. D. G., Rannikko, S., CASLAKE, M. J., Bedford, D. K., Stewart, P., Yki‐Järvinen, H., Shepherd, J., & Taskinen, M. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.7.1454 · Cited by 178 · see citing works

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173 · see citing works

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C. L., Musi, N., DeFronzo, R. A., & Cersósimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 157 · see citing works

GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats

Qin, X., Shen, H., Liu, M., Yang, Q., Zheng, S., Sabo, M., D’Alessio, D. A., & Tso, P. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00303.2004 · Cited by 153 · see citing works

Intestinal Insulin Resistance and Aberrant Production of Apolipoprotein B48 Lipoproteins in an Animal Model of Insulin Resistance and Metabolic Dyslipidemia

Federico, L. M., Naples, M., Taylor, D., & Adeli, K. (2006) · Diabetes · doi:10.2337/db04-1084 · Cited by 132 · see citing works

Intestinal lipoprotein overproduction in insulin-resistant states

Adeli, K., & Lewis, G. F. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ffaf82 · Cited by 130 · see citing works

Gut-liver interaction in triglyceride-rich lipoprotein metabolism

Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 126 · see citing works

Both Intestinal and Hepatic Lipoprotein Production Are Stimulated by an Acute Elevation of Plasma Free Fatty Acids in Humans

Duez, H., Lamarche, B., Valéro, R., Pavlic, M., Proctor, S. D., Xiao, C., Szeto, L., Patterson, B. W., & Lewis, G. F. (2008) · Circulation · doi:10.1161/circulationaha.107.739888 · Cited by 114 · see citing works

The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action

Ayala, J. E., Bracy, D. P., James, F. D., Julien, B. M., Wasserman, D. H., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0945 · Cited by 114 · see citing works

Insulin Acutely Inhibits Intestinal Lipoprotein Secretion in Humans in Part by Suppressing Plasma Free Fatty Acids

Pavlic, M., Xiao, C., Szeto, L., Patterson, B. W., & Lewis, G. F. (2009) · Diabetes · doi:10.2337/db09-1297 · Cited by 102 · see citing works

Intestinal Lipoprotein Overproduction, a Newly Recognized Component of Insulin Resistance, Is Ameliorated by the Insulin Sensitizer Rosiglitazone: Studies in the Fructose-Fed Syrian Golden Hamster

Lewis, G. F., Uffelman, K. D., Naples, M., Szeto, L., Haidari, M., & Adeli, K. (2004) · Endocrinology · doi:10.1210/en.2004-1143 · Cited by 99 · see citing works

Ameliorated Hepatic Insulin Resistance Is Associated with Normalization of Microsomal Triglyceride Transfer Protein Expression and Reduction in Very Low Density Lipoprotein Assembly and Secretion in the Fructose-fed Hamster

Carpentier, A. C., Taghibiglou, C., Leung, N. M., Szeto, L., Iderstine, S. C. V., Uffelman, K. D., Buckingham, R. E., Adeli, K., & Lewis, G. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204568200 · Cited by 97 · see citing works

GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet

Parlevliet, E. T., van Weenen, J. E. D. L., Romijn, J. A., & Pijl, H. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00191.2010 · Cited by 78 · see citing works

Mechanism of intestinal lipoprotein overproduction in insulin resistant humans

Duez, H., Pavlic, M., & Lewis, G. F. (2008) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2008.05.013 · Cited by 62 · see citing works

Effects of Acute Hyperglucagonemia on Hepatic and Intestinal Lipoprotein Production and Clearance in Healthy Humans

Xiao, C., Pavlic, M., Szeto, L., Patterson, B. W., & Lewis, G. F. (2010) · Diabetes · doi:10.2337/db10-0763 · Cited by 60 · see citing works

Intestinal Lipoprotein Production Is Stimulated by an Acute Elevation of Plasma Free Fatty Acids in the Fasting State: Studies in Insulin-Resistant and Insulin-Sensitized Syrian Golden Hamsters

Lewis, G. F., Naples, M., Uffelman, K. D., Leung, N. M., Szeto, L., & Adeli, K. (2004) · Endocrinology · doi:10.1210/en.2003-1559 · Cited by 56 · see citing works

Effects of Glucagon-like Peptide 1 on the Hepatic Glucose Metabolism

D’Alessio, D. A., Vahl, T. P., & Prigeon, R. L. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826172 · Cited by 52 · see citing works

Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects

Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50 · see citing works

Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study

Schwartz, S. L., Ratner, R. E., Kim, D. D. H., Qu, Y., Fechner, L. L., Lenox, S. M., & Holcombe, J. H. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.004 · Cited by 46 · see citing works

Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver

Zheng, D., Ionut, V., Mooradian, V., Stefanovski, D., & Bergman, R. N. (2008) · Diabetes · doi:10.2337/db08-0875 · Cited by 43 · see citing works

Exenatide can reduce glucose independent of islet hormones or gastric emptying

Ionut, V., Zheng, D., Stefanovski, D., & Bergman, R. N. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90222.2008 · Cited by 35 · see citing works

VLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin

Lewis, G. F., Zinman, B., Uffelman, K. D., Szeto, L., Weller, B., & Steiner, G. A. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.267.4.e566 · Cited by 35 · see citing works

Vitamin D Analogues in Insulin-Dependent Diabetes Mellitus and Other Autoimmune Diseases: A Therapeutic Perspective

Mauricio, D., Mandrup-Poulsen, T. R., & Nerup, J. (1996) · Diabetes/Metabolism Reviews · doi:10.1002/(sici)1099-0895(199603)12:1 · Cited by 33 · see citing works

Acute Dipeptidyl Peptidase-4 Inhibition Rapidly Enhances Insulin-Mediated Suppression of Endogenous Glucose Production in Mice

Duez, H., Smith, A. C., Xiao, C., Giacca, A., Szeto, L., Drucker, D. J., & Lewis, G. F. (2008) · Endocrinology · doi:10.1210/en.2008-1137 · Cited by 26 · see citing works

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · see citing works

The Discovery and Development of Liraglutide and Semaglutide

Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · see citing works

The Cardiovascular Biology of Glucagon-like Peptide-1

Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · see citing works

New insights into the pathophysiology of dyslipidemia in type 2 diabetes

Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440 · see citing works

Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review

Vinarov, Z., Abdallah, M., Agúndez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M. F., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 380 · see citing works

Cardiovascular Actions of Incretin-Based Therapies

Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358 · see citing works

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · see citing works

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function

Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302 · see citing works

Safety of Semaglutide

Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · see citing works

Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis

Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232 · see citing works

Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol

Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · see citing works

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

Sarafidis, P. A., Ferro, C. J., Morales, E., Ortíz, A., Małyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J. M., Fouque, D. P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 212 · see citing works

New insights into the regulation of chylomicron production

Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194 · see citing works

Postprandial hypertriglyceridemia as a coronary risk factor

Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182 · see citing works

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Yabut, J. M., & Drucker, D. J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 180 · see citing works

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · see citing works

Recent advances in pharmacotherapy for hypertriglyceridemia

Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166 · see citing works

Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide

Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157 · see citing works

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk

Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119 · see citing works

Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans

Jácome-Sosa, M., & Parks, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000080 · Cited by 118 · see citing works

Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes

Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106 · see citing works

Review article: a comparison of glucagon‐like peptides 1 and 2

Janssen, P., Rotondò, A., Mulè, F., & Tack, J. F. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12092 · Cited by 105 · see citing works

Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action

Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104 · see citing works

High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men

Dash, S., Xiao, C., Morgantini, C., Szeto, L., & Lewis, G. F. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302342 · Cited by 102 · see citing works

Metabolic control via nutrient-sensing mechanisms: role of taste receptors and the gut-brain neuroendocrine axis

Raka, F., Farr, S., Kelly, J., Stoianov, A. M., & Adeli, K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00036.2019 · Cited by 98 · see citing works

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study

Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., & Imaoka, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12534 · Cited by 98 · see citing works

Glucagon-Like Peptide-2 Regulates Release of Chylomicrons From the Intestine

Dash, S., Xiao, C., Morgantini, C., Connelly, P. W., Patterson, B. W., & Lewis, G. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.037 · Cited by 97 · see citing works

Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96 · see citing works

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 93 · see citing works

Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics

Julve, J., Martín-Campos, J. M., Escolá‐Gil, J. C., & Blanco‐Vaca, F. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.004 · Cited by 85 · see citing works

Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives

Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 83 · see citing works

Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies

Chan, D. C., Pang, J., Romic, G., & Watts, G. F. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0309-9 · Cited by 80 · see citing works

The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications

Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 79 · see citing works

Recent advances in triacylglycerol mobilization by the gut

Xiao, C., Stahel, P., Carreiro, A. L., Buhman, K. K., & Lewis, G. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.12.001 · Cited by 77 · see citing works

Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74 · see citing works

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus

Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Sberna, A.-L., Petit, J.-M., Degrace, P., & Demizieux, L. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310990 · Cited by 75 · see citing works

Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans

Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 73 · see citing works

Modification of lipoprotein metabolism and function driving atherogenesis in diabetes

Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72 · see citing works

How glucagon-like peptide 1 receptor agonists work

Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71 · see citing works

The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials

Austregésilo de Athayde De Hollanda Morais, B., Martins Prizão, V., de Moura de Souza, M., Ximenes Mendes, B., Rodrigues Defante, M. L., Cosendey Martins, O., & Rodrigues, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108834 · Cited by 68 · see citing works

The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis

Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63 · see citing works

Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain–Gut Axis

Farr, S., Baker, C., Naples, M., Taher, J., Iqbal, J., Hussain, M. M., & Adeli, K. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304873 · Cited by 62 · see citing works

Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation

Xie, C., Jones, K. L., Rayner, C. K., & Wu, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090790 · Cited by 62 · see citing works

GLP-1 based therapies: clinical implications for gastroenterologists

Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61 · see citing works

Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism

Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60 · see citing works

New and emerging regulators of intestinal lipoprotein secretion

Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.047 · Cited by 59 · see citing works

Novel Role of Enteral Monosaccharides in Intestinal Lipoprotein Production in Healthy Humans

Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300769 · Cited by 56 · see citing works

Twelve weeks of exenatide treatment increases [18F] fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males

Janssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54 · see citing works

Intestinal lipid absorption and transport in type 2 diabetes

Vergès, B. L. (2022) · Diabetologia · doi:10.1007/s00125-022-05765-8 · Cited by 51 · see citing works

Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials

Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 51 · see citing works

Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors

Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 52 · see citing works

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

Brunell, S. C., Toth, P. P., Ramı́rez, G., Cobble, Chilton, & Chiquette (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37969 · Cited by 49 · see citing works

Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge

Liu, D., Pang, J., Shao, W., Gu, J., Zeng, Y., He, H. H., Ling, W., Qian, X., & Jin, T. (2021) · Hepatology · doi:10.1002/hep.31856 · Cited by 48 · see citing works

Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment.

Higgins, V., & Adeli, K. (2017) · PubMed Central · Cited by 47 · see citing works

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis

Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 51 · see citing works

Oral Glucose Mobilizes Triglyceride Stores From the Human Intestine

Xiao, C., Stahel, P., Carreiro, A. L., Hung, Y.-H., Dash, S., Bookman, I. D., Buhman, K. K., & Lewis, G. F. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.002 · Cited by 46 · see citing works

Postprandial Dyslipidemia, Hyperinsulinemia, and Impaired Gut Peptides/Bile Acids in Adolescents with Obesity

Higgins, V., Asgari, S., Hamilton, J. K., Wolska, A. T., Remaley, A. T., Hartmann, B., Holst, J. J., & Adeli, K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz261 · Cited by 44 · see citing works

Postprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions

Jácome-Sosa, M., Parks, E. J., Bruno, R. S., Tasali, E., Lewis, G. F., Schneeman, B. O., & Rains, T. M. (2016) · Advances in Nutrition · doi:10.3945/an.115.010397 · Cited by 46 · see citing works

Enteroendocrine Regulation of Nutrient Absorption

McCauley, H. A. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz191 · Cited by 43 · see citing works

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 42 · see citing works

Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes

Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Pietiläinen, K. H., Ainola, M., Hakkarainen, A., Lundbom, N., Fuchs, J., Thorsell, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14328 · Cited by 40 · see citing works

Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism

Lutz, T. A., & Osto, E. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000293 · Cited by 39 · see citing works

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 39 · see citing works

Role of the Gut in Diabetic Dyslipidemia

Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 39 · see citing works

Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile

Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35 · see citing works

Diabetic Dyslipidemia: From Evolving Pathophysiological Insight to Emerging Therapeutic Targets

Ng, D. S. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.062 · Cited by 35 · see citing works

Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk

Bozzetto, L., Annuzzi, G., Ragucci, M., Donato, O. D., Pepa, G. D., Corte, G. D., Griffo, E., Anniballi, G., Giacco, A., Mancini, M., et al. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.011 · Cited by 34 · see citing works

Bile acid treatment and FXR agonism lower postprandial lipemia in mice

Farr, S., Stankovic, B., HOFFMAN, S. S., Masoudpoor, H., Baker, C., Taher, J., Dean, A. E., Anakk, S., & Adeli, K. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00386.2018 · Cited by 33 · see citing works

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance

Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01176 · Cited by 32 · see citing works

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Engelbrechtsen, L., Lundgren, J. R., Albrechtsen, N. J. W., Mahendran, Y., Iepsen, E. W., Finocchietto, P. V., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., et al. (2017) · Obesity Science & Practice · doi:10.1002/osp4.133 · Cited by 32 · see citing works

GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance

Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35 · see citing works

Effect of sitagliptin therapy on triglyceride‐rich lipoprotein kinetics in patients with type 2 diabetes

Tremblay, A. J., Lamarche, B., Kelly, I., Charest, A., Lépine, M. ‐., Droit, A., & Couture, P. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12359 · Cited by 31 · see citing works

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2

Mulvihill, E. E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000495 · Cited by 29 · see citing works

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30 · see citing works

Lipid effects of glucagon-like peptide 1 receptor analogs

Berberich, A. J., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000750 · Cited by 30 · see citing works

Functional food addressing heart health: do we have to target the gut microbiota?

Ryan, P. M., Ross, R. P., Fitzgerald, G. F., Caplice, N. M., & Stanton, C. (2015) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000224 · Cited by 28 · see citing works

Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association

Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 28 · see citing works

GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment

Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 29 · see citing works

Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease

Mori, K., Ishida, T., Yasuda, T., Monguchi, T., Sasaki, M., Kondo, K., Hasokawa, M., Nakajima, H., Haraguchi, Y., Sun, L., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.02.005 · Cited by 27 · see citing works

GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice

Taher, J., Baker, C., ALVARES, D. C. L., Ijaz, L., Hussain, M. M., & Adeli, K. (2018) · Endocrinology · doi:10.1210/en.2018-00416 · Cited by 26 · see citing works

Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia

Lewis, G. F., & Hegele, R. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00284-9 · Cited by 24 · see citing works

A micro-nano optogenetic system based on probiotics for in situ host metabolism regulation

Zhang, X., Ma, N., Ling, W., Pang, G., Sun, T., Liu, J., Pan, H., Cui, M., Han, C., Yang, C., et al. (2022) · Nano Research · doi:10.1007/s12274-022-4963-5 · Cited by 24 · see citing works

GLP-1 (Glucagon-Like Peptide-1) Is Physiologically Relevant for Chylomicron Secretion Beyond Its Known Pharmacological Role

Nahmias, A., Stahel, P., Tian, L., Xiao, C., & Lewis, G. F. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316311 · Cited by 23 · see citing works

Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents

Ryan, P. M., Patterson, E., Kent, R. M., Stack, H. M., O’Connor, P. M., Murphy, K., Peterson, V. L., Mandal, R., Wishart, D. S., Dinan, T. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14010-x · Cited by 23 · see citing works

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men

Matikainen, N., Björnson, E., Söderlund, S., Borén, C., Eliasson, B., Pietiläinen, K. H., Bogl, L. H., Hakkarainen, A., Lundbom, N. M. I., Rivellese, A. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145890 · Cited by 22 · see citing works

Multi-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks

Stahel, P., Xiao, C., Nahmias, A., Tian, L., & Lewis, G. F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab008 · Cited by 22 · see citing works

Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism

HOFFMAN, S. S., & Adeli, K. (2024) · Medical Review · doi:10.1515/mr-2024-0011 · Cited by 22 · see citing works

Central nervous system regulation of intestinal lipid and lipoprotein metabolism

Farr, S., Taher, J., & Adeli, K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000254 · Cited by 21 · see citing works

Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors

Bistola, V., Lambadiari, V., Dimitriadis, G., Ioannidis, I., Makrilakis, K., Tentolouris, N., Τσάπας, Α., & Parissis, J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9674-3 · Cited by 21 · see citing works

Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue

Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 20 · see citing works

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

Zhong, J., Kankanala, S., & Rajagopalan, S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000340 · Cited by 19 · see citing works

The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia

Novodvorský, P., & Haluzı́k, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00982-3 · Cited by 19 · see citing works

Effect of liraglutide on dietary lipid‐induced insulin resistance in humans

Koška, J., Lopez, L. K., D’Souza, K. M., Osredkar, T., Deer, J., Kurtz, J., Salbe, A. D., Harman, S. M., & Reaven, P. D. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13037 · Cited by 20 · see citing works

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus

Chiba, Y., Yamakawa, T., Tsuchiya, H., Oba, M. S., Suzuki, D., Danno, H., Takatsuka, Y., Shigematsu, H., Kaneshiro, M., & Terauchi, Y. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3464w · Cited by 18 · see citing works

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review

Teshome, G., Ambachew, S., Fasil, A., & Abebe, M. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265631 · Cited by 18 · see citing works

GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss

Pepa, G. D., Patrício, B. G., Carli, F., Sabatini, S., Astiarraga, B., Ferrannini, E., Camastra, S., & Gastaldelli, A. (2024) · Diabetes · doi:10.2337/db23-0972 · Cited by 17 · see citing works

Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract

Morrow, N. M., Hanson, A. A., & Mulvihill, E. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703966 · Cited by 17 · see citing works

GLP1, an Important Regulator of Intestinal Lipid Metabolism

Dallinga‐Thie, G. M., & Nieuwdorp, M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305479 · Cited by 16 · see citing works

Alogliptin benzoate for the treatment of type 2 diabetes

Seino, Y., & Yabe, D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.898750 · Cited by 15 · see citing works

Diagnosis and management of lipodystrophy: a practical update

Stears, A. J., & Hames, C. (2014) · Clinical Lipidology · doi:10.2217/clp.14.13 · Cited by 15 · see citing works

Incretin-based therapies: Effects on plasma lipids and potential mechanisms

Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2009) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 276 · see citing works

Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans

(2016)

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173 · see citing works

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide

Voukali, M., Kastrinelli, I., Stragalinou, S., Tasiopoulou, D., Paraskevopoulou, P., Katsilambros, N., Kokkinos, A. D., Tentolouris, N., & Ioannidis, I. (2014) · Journal of Diabetes Research · doi:10.1155/2014/304032 · Cited by 26 · see citing works